Partners

King's College London

King's College London

King's College London is currently the largest centre for the education of healthcare professionals in Europe, with more Medical Research Council Centres than any other.  Based in the heart of London, King's has an outstanding reputation for providing world-class teaching and cutting-edge research.

Its Department of Clinical Neuroscience is one of the major academic units of clinical neuroscience in the UK. The Department host 10 full Professors and is closely allied with the Department of Clinical Neuroscience at King’s College Hospital in which there are now 38 Consultant Neurologists.

 

 

Michael Rose - Consultant Neurologist

Michael Rose (PhD, FRCP) : Editor Cochrane Neuromuscular Disease Group. More than 50 original articles in journals. Systematic review writer and outcome measurement expert.

 

 

Joanne Auld - Registry Co-ordinator

 Jo Auld (MBA) joined King's College London in January 2008.  A business analyst and process engineer, Jo has extensive experience in programme management, application development and implementation.  As Research Project Manager and Registry Coordinator Jo is responsible for management of all KCLSM activities relating to the TREAT-NMD network.  She is the curator and primary point of contact for all issues related to the TREAT-NMD Registry of Outcome Measures and coordinates integration with related NMD outcome measures research activities. 

Jo's professional background encompasses financial management, higher education and research.  In addition to extensive experience in Corporate Governance and Executive Support, Jo also holds post technician qualifications in scientific photography and successfully managed her own photography business for a number of years.  She is currently investigating ways to utilise her photography to raise funds for charities.

 

Reza Sadjadi - Clinical Fellow in Neurology


 

 
 


TREAT-NMD Coordination Office: T: +44 191 241 8605 Fax: +44 191 241 8770 E:
FP6 Logo TREAT-NMD is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of the European Union’s FP6 under contract number LSHM-CT-2006-036825 EU flag